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Abstract: The reaction of indoline with a substituted benzoyl chloride in the 
presence of K2CO3 in THF gave compound 4. Compound 4 was subjected to 
chlorosulphonation to obtain compound 5. Condensation of aromatic amines 
with compound 5 led to the synthesis of indoline derivatives 6(a–f). Similarly, 
5-nitroindoline was treated with a substituted benzoyl chloride to obtain the 
nitro compound 9, which was reduced using stannous chloride and reacted 
further with aromatic sulphonyl chloride to obtain the indoline derivatives 
11(a–e). These compounds were tested for antibacterial, anti-tuberculosis and 
antifungal activity. Some of them showed very good activity against some 
gram-positive and gram negative bacteria, fungal strains and also Mycobacte-
rium tuberculosis. All of the synthesized compounds were subjected to anti-
oxidant activity testing using the in vitro DPPH assay and most of them show-
ed very good activity. 
Keywords: indoline; antioxidant activity; antifungal; anti-tuberculosis and anti-
bacterial activity. 
INTRODUCTION 
Indoline and other related ring systems possess several interesting biological 
activities. The indolines are also interesting structural scaffolds and have, for ex-
ample, been evaluated as 5-HT2C receptor agonists for the treatment of obesity.1 
Factor Xa (FXa) is well known to play a pivotal role in blood coagulation; hence, 
an FXa inhibitor is a promising drug candidate for prophylaxis and treatment of 
thromboembolic diseases. Some indoline derivatives have been found to show 
very good FXa inhibitory activities.2 Indoline derivatives have also been found to 
show an antagonistic effect on progesterone receptors.3 In addition, indolines have 
been evaluated for antimicrobial activity.4 Owing to the biological importance of 
indolines and in continuation of our work on the synthesis of biologically im-
portant heterocyclic compounds, the synthesis of some indolines is reported herein. 
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RESULTS AND DISCUSSION 
In present work, the synthesis of novel indoline derivatives is reported start-
ing with the substituted benzoyl chloride 2, which was prepared by the reaction 
of 4-(aminosulfonyl)benzoic acid with SOCl2 and DMF. Treatment of 2 with 
indoline 3 in the presence of K2CO3 in THF afforded compound 4. Compound 4 
was subjected to chlorosulphonation to obtain compound 5, which on reaction 
with aromatic amines in presence of pyridine and a catalytic amount of DMAP 
using THF as the solvent yielded the indoline derivatives 6(a–f). The synthetic 
scheme to 6(a–f) is shown in Scheme 1 and the structural data of 6(a–f) are given 
in Table I. 
 
Scheme 1. 
Similarly, 5-nitroindoline (8) on treatment with compound 7 gave the nitro 
derivative 9, which was further reduced by stannous chloride to the amino deri-
vative 10. The amino derivative on treatment with aromatic sulphonyl chlorides 
gave the indoline derivatives 11(a–e). The synthetic scheme to 11(a–e) is shown 
in Scheme 2 and the structural data of 11(a–e) are given in Table II. 
The compounds 6(a–f) and 11(a–e) were characterized by FTIR, 
1H-NMR 
and mass spectroscopy. 
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TABLE I. Structure of the synthesized compounds 6(a–f) 
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Compound 6a. Yield: 89 %; white crystalline; m.p. 119 °C; Anal. Calcd. for 
C28H30FN5O6S2: C, 54.62; H, 4.91; N, 11.37 %. Found: C, 54.61; H, 4.90; N, 
11.36 %. IR (KBr, cm–1): 3452 (stretching of NH), 3047 (stretching of N=C–H), 
2937, 2840 (stretching of C–H), 1634 (stretching of amide C=O), 1246 (stretch-
ing of C–F), 1050 (stretching of C–O). 1H-NMR (400 MHz, DMSO-d6, δ / ppm) 
2.85 (4H, t, morpholine CH2), 2.90 (3H, s, NCH3), 3.09 (2H, t, indoline CH2), 
3.16 (3H, s, NCH3), 3.68 (4H, t, morpholine CH2), 4.01 (2H, t, indoline CH2), 
6.53–7.88 (10H, m, aromatic protons), 8.26 (1H, s, N=CH), 10.52 (1H, s, NH). 
MS (m/z): 615 (M+) with all isotopic and other peaks. 
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Scheme 2. 
Compound 6b. Yield: 76 %; grey microcrystalline; m.p; 146 °C. Anal. Calcd. 
for C26H27N5O6S2: C, 54.82; H, 4.78; N, 12.29 %. Found: C, 54.81; H, 4.77; N, 
12.28 %. IR (KBr, cm–1): 3455 (stretching of NH), 3050 (stretching of N=C–H), 
2927, 2830 (stretching of C–H), 1632 (stretching of amide C=O). 1H-NMR (400 
MHz, DMSO-d6, δ / ppm): 2.67 (3H, s, NHCOCH3), 2.71 (2H, t, indoline CH2), 
2.90 (3H, s, NCH3), 3.16 (3H, s, NCH3), 3.90 (2H, t, indoline CH2), 6.83–8.25 
(11H, m, aromatic protons), 8.28 (1H, s, N=CH), 8.72 (1H, s, NHCO), 10.25 (1H, 
s, NHSO2). MS (m/z): 569 (M+) with all isotopic and other peaks. 
Compound  6c. Yield: 90 %; red powder; m.p. 132 °C; Anal. Calcd. for 
C33H33N5O8S3: C, 54.76; H, 4.60; N, 9.68 %. Found: C, 54.75; H, 4.61; N, 9.67 %. 
IR (KBr, cm–1): 3450 (stretching of NH), 3048 (stretching of N=C–H), 2929, 
2832 (stretching of C–H), 1633 (stretching of amide C=O). 1H-NMR (400 MHz, 
DMSO-d6, δ / ppm): 2.37 (3H, s, ArCH3), 2.92 (3H, s, NCH3), 3.09 (2H, t, indo-
line CH2), 3.16 (3H, t, NCH3), 3.42 (2H, s, CH2CO), 3.98 (2H, t, indoline CH2), 
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6.99–8.25 (15H, m, aromatic protons), 8.26 (1H, s, N=CH), 8.57 (1H, s, NHSO2), 
10.52 (1H, s, CONHSO2). MS (m/z): 723 (M+) with all isotopic and other peaks. 
TABLE II. Structure of the synthesized compounds 11(a–e) 
Compound R 
11a 
N
Cl
11b 
Br
11c 
11d 
O O
11e 
O
   
Compound 6d. Yield: 85 %; brown crystalline; m.p. 124 °C. Anal. Calcd. for 
C34H29BrN4O7S2: C, 54.47; H, 3.90; N, 7.47 %. Found: C, 54.46; H, 3.89; N, 
7.46 %. IR (KBr, cm–1): 3450 (stretching of NH), 3048 (stretching of N=C–H), 
2929, 2832 (stretching of C–H), 1682 (stretching of Ar–C=O), 1633 (stretching 
of amide C=O). 
1H-NMR (400 MHz, DMSO-d6, δ / ppm): 2.51 (3H, s, ArCH3), 
2.76 (2H, t, indoline CH2), 3.07 (3H, s, NCH3), 3.15 (3H, s, NCH3), 4.00 (2H, t, 
indoline CH2), 7.41–8.01 (14H, m, aromatic protons), 8.26 (1H, s, N=CH), 10.52 
(1H, s, NH). MS (m/z): 749 (M+) with all isotopic and other peaks. 
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Compound  6e. Yield: 88 %; brown microcrystalline; m.p. 132 °C. Anal. 
Calcd. for C35H32N4O8S2: C, 59.99; H, 4.60; N, 7.99 %. Found: C, 59.98; H, 
4.59; N, 7.99 %. IR (KBr, cm–1): 3438 (stretching of NH), 3052 (stretching of 
N=C–H), 2928, 2842 (stretching of C-H), 1685 (stretching of Ar–C=O), 1635 
(stretching of amide C=O). 1H-NMR (400 MHz, DMSO-d6, δ / ppm): 2.53 (3H, 
s, ArCH3), 3.08 (2H, t, indoline CH2), 3.15 (6H, s, N(CH3)2), 3.88 (3H, s, OCH3), 
4.03 (2H, t, indoline CH2), 7.10–8.05 (14H, m, aromatic protons), 8.26 (1H, s, 
N=CH), 10.52 (1H, s, NH). MS (m/z): 700 (M+) with all isotopic and other peaks. 
Compound 6f. Yield: 95 %; white needles; m.p. 160 °C; Anal. Calcd. for 
C27H30N6O5S2: C, 55.65; H, 5.19; N, 14.42 %. Found: C, 55.64; H, 5.18; N, 
14.42 %. IR (KBr, cm–1): 3434 (stretching of NH), 3050 (stretching of N=C–H), 
2927, 2852 (stretching of C–H), 1631 (stretching of amide C=O). 1H-NMR (400 
MHz, DMSO-d6, δ / ppm): 2.94 (6H, s, N(CH3)2), 3.05 (2H, t, indoline CH2), 
3.19 (4H, t, piperazine CH2), 3.63 (4H, t, piperazine CH2), 4.06 (2H, s, indoline 
CH2), 6.89–8.45 (11H, m, aromatic protons), 8.26 (1H, s, N=CH). MS (m/z): 582 
(M+) with all isotopic and other peaks. 
Compound 11a. Yield: 76 %; red crystals; m.p. 155 °C; Anal. Calcd. for 
C30H28ClN3O7S: C, 59.06; H, 4.63; N, 6.89 %. Found: C, 59.05; H, 4.62; N, 
6.88 %. IR (KBr, cm–1): 3486 (stretching of NH), 2902, 2852 (stretching of C–H), 
1632 (stretching of amide C=O), 1240 (stretching of C–O). 
1H-NMR (400 MHz, 
DMSO-d6, δ / ppm): 2.98 (2H, t, indoline CH2), 3.73 (6H, s, OCH3), 3.97 (2H, t, 
indoline CH2), 4.22 (4H, m, OCH2), 6.83–9.03 (13H, m, aromatic protons), 10.52 
(1H, s, NH). MS (m/z): 609 (M+) with all isotopic and other peaks. 
Compound 11b. Yield: 65 %; white needles; m.p. 99 °C; Anal. Calcd. for 
C31H29BrN2O7S: C, 56.97; H, 4.47; N, 4.29 %. Found: C, 56.96; H, 4.46; N, 
4.28 %. IR (KBr, cm–1): 3488 (stretching of NH), 2922, 2852 (stretching of C–H), 
1632 (stretching of amide C=O), 1246 (stretching of C–O). 1H-NMR (400 MHz, 
DMSO-d6, δ / ppm): 3.00 (2H, t, indoline CH2), 3.73 (6H, s, OCH3), 3.98 (2H, t, 
indoline CH2), 4.22 (4H, m, OCH2), 6.84–7.79 (14H, m, aromatic protons), 10.25 
(1H, s, NH). MS (m/z): 653 (M+) with all isotopic and other peaks. 
Compound 11c. Yield: 78 %; grey crystals; m.p. 106 °C; Anal. Calcd. for 
C37H34N2O7S: C, 68.29; H, 5.27; N, 4.30 %. Found: C, 68.28; H, 5.26; N, 4.29 %. 
IR (KBr, cm–1): 3488 (stretching of NH), 2922, 2852 (stretching of C–H), 1632 
(stretching of amide C=O), 1246 (stretching of C–O). 1H-NMR (400 MHz, 
DMSO-d6, δ / ppm): 3.00 (2H, t, indoline CH2), 3.71 (6H, s, OCH3), 3.97 (2H, t, 
indoline CH2), 4.22 (4H, m, OCH2), 6.82–7.85 (19H, m, aromatic protons), 10.52 
(1H, s, NH). MS (m/z): 650 (M+) with all isotopic and other peaks. 
Compound 11d. Yield: 80 %; yellow crystals; m.p. 105 °C; Anal. Calcd. for 
C34H30N2O9S: C, 63.54; H, 4.71; N, 4.36 %. Found: C, 63.54; H, 4.71; N, 4.35 %. 
IR (KBr, cm–1): 3486 (stretching of NH), 2902, 2852 (stretching of C–H), 1690 
(stretching of coumarin CO), 1633 (stretching of amide C=O), 1245 (stretching 
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of C–O). 1H-NMR (400 MHz, DMSO-d6, δ / ppm): 3.00 (2H, t, indoline CH2), 
3.80 (6H, s, OCH3), 3.98 (2H, t, indoline CH2), 4.41 (4H, m, OCH2), 6.60–8.21 
(15H, m, aromatic protons), 10.52 (1H, s, NH). MS (m/z): 642 (M+) with all iso-
topic and other peaks. 
Compound 11e. Yield: 81 %; yellow crystals; m.p. 111 °C; Anal. Calcd. for 
C33H32N2O8S: C, 64.27; H, 5.23; N, 4.54 %. Found: C, 64.27; H, 5.22; N, 4.53 %. 
IR (KBr, cm–1): 3445 (stretching of NH), 3198, 2935, 2842 (stretching of C–H), 
1720 (stretching of COCH3), 1632 (stretching of amide C=O), 1250 (stretching 
of C–O). 
1H-NMR (400 MHz, DMSO-d6, δ / ppm): 2.04 (3H, s, COCH3), 3.00 
(2H, t, indoline CH2), 3.77 (6H, s, OCH3), 4.02 (2H, t, indoline CH2), 4.24 (4H, 
m, OCH2), 6.81–7.71 (14H, m, aromatic protons), 10.17 (1H, s, NH); MS (m/z): 
616 (M+) with all isotopic and other peaks. 
The compounds 6(a–f) and 11(a–e) were tested for their antioxidant, anti-
bacterial, antifungal and anti-tuberculosis activities. 
Amongst the compounds screened for antioxidant activity, 6a, 6b, 6e, 6f and 
11 (a–e) showed very good antioxidant activities, as shown in Table III. 
All the screened compounds, except 6b, 6c, 11d and 11e, exhibited very good 
antifungal and antibacterial activities, as shown in Tables IV and V, respectively. 
TABLE III. Antioxidant activity (%) of the compounds 
Compound 
Concentration / µg ml-1 
200 100  50 
L-Ascorbic  acid  99.2 99 98.8 
6a  93.5 92.00  88.05 
6b  90.00 88.05 85.00 
6c  28.05 24.36  20.7 
6d  57.9 48.0 28.2 
6e  98.6 98.5 89.8 
6f  98.4 98.0 85.8 
11a  99.00 97.2  93.6 
11b  94.2 93.2 92.6 
11c  95.00 92.40 78.05 
11d  94.55 92.40 85.05 
11e  91.70 83.25 70.22 
TABLE IV. Antifungal activity of the compounds 
Compound 
Concentration / µg ml-1 
5  25 50  100 250 5 25 50  100 250 5 25 50  100  250 
A. niger  A. clavatus  C. albicans 
Griseofulvin  19 23 25 25 28 18 21 22 22 24  –  –  –  –  – 
Nystatin  18 19 24 29 29 18 21 24 25 26  –  –  –  –  – 
6a  –  10 15 17 19  –  11 16 17 19  –  14 16 17 20 
6d  –  12 16 19 21  –  12 15 19 22  –  12 15 20 22 
6e  –  13 17 19 22  –  13 17 18 20  –  15 17 19 21 
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TABLE IV. Continued 
Compound 
Concentration / µg ml-1 
5 25 50  100 250 5 25 50  100 250 5 25 50  100  250 
A. niger  A. clavatus  C. albicans 
6f  –  14 16 18 19  –  13 15 18 19  –  15 17 19 20 
11a  –  14 16 19 20  –  11 17 18 19  –  12 17 18 21 
11b  –  12 15 18 20  –  12 15 18 19  –  13 15 18 19 
11c  –  13 16 20 21  –  13 16 18 20  –  15 16 19 20 
TABLE V. Antibacterial activity of the compounds 
Compound 
Concentration / µg ml-1 
25  50 100  250 25 50 100 250 25 50 100 250 25 50 100  250 
E. coli  P. aeruginosa  S. aureus  S. pyogenes 
Ampicillin  15 16 19 20 15 15 18 20 14 16 18 19 13 14 16 20 
Ciprofloxacin 23 28 28 28 23 24 26 27 19 21 21 22 19 21 22 22 
Norfloxacin  25 26 27 29 19 21 23 23 19 20 21 21 22 25 26 28 
6a  13 15 17 21 12 14 18 21 12 14 17 19 11 12 15 17 
6d  16 18 20 22 15 17 19 22 11 12 15 17 12 14 17 20 
6e  13 13 15 17 11 12 15 16 15 18 20 22 11 14 16 18 
6f  11 11 14 15 11 12 13 15 12 14 15 17 11 13 15 17 
11a  11 14 16 17 11 14 17 19 12 14 15 15 11 13 14 15 
11b  11 13 17 17 10 12 15 18 14 16 19 23 12 14 16 17 
11c  11 13 15 15 10 13 14 16 17 19 19 24 12 15 17 19 
Compounds 6a (MIC = 100 μg/ml) and 6f (MIC = 62.5 μg/ml) showed pro-
mising anti-tuberculosis activity, as shown in Table VI. 
TABLE VI. Anti-tuberculosis activity of the compounds 
Compound  MIC / μg ml-1 
Steptomycin 4 
Isoniazid 0.2 
Rifampicin 40 
Ethambutol 2 
6a  100 
6d  250 
6e  250 
6f  62.5 
11a  500 
11b  1000 
11c  >1000 
EXPERIMENTAL 
All the recorded melting points were determined in an open capillary and are uncor-
rected. The IR spectra were recorded on a Perkin-Elmer FTIR spectrophotometer in KBr 
discs. The 1H-NMR spectra were recorded on a 400 MHz spectrophotometer in DMSO-d6 as 
solvent and TMS as the internal standard. The mass spectra were obtained using a Waters 
mass spectrometer. 
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4-(2,3-Dihydro-1H-indol-1-ylcarbonyl)-N-[(1E)-(dimethylamino)methylene]-
benzenesulphonamide (4) 
Compounds  2 (0.010 mol) and 3 (0.010 mol) were dissolved in THF together with 
K2CO3. The reaction mixture was stirred at room temperature for 4 h. The reaction mixture 
was then poured into water and extracted with EtOAc. The organic layer was separated, dried 
over Na2SO4 and concentrated under vacuum. 
Compound 4. Yield: 85 %, red crystalline, m.p. 161 °C. Anal. Calcd. for C18H19N3O3S: 
C, 60.49; H, 5.36; N, 11.76 %. Found: C, 60.48; H, 5.35; N, 11.76 %. IR (KBr, cm-1): 3047 
(stretching of N=C–H), 2937, 2840 (stretching of C–H), 1634 (stretching of amide C=O). 1H- 
-NMR (400 MHz, DMSO-d6, δ / ppm): 2.94 (3H, s, NCH3), 3.09 (2H, t, indoline CH2), 3.17 
(3H, s, NCH3), 3.98 (2H, t, indoline CH2), 7.07–7.87 (8H, m, aromatic protons), 8.27 (1H, s, 
N=CH). MS (m/z): 357 (M+) with all isotopic and other peaks. 
1-[4-({[(1E)-(Dimethylamino)methylene]amino}sulphonyl)benzoyl]indoline-5-sulphonyl 
chloride (5)  
Compound 4 (0.010 mol) was added in portions to a solution of chlorosulphonic acid (10 
ml) at 0 °C and stirred for 30 min. The reaction mixture was cooled to room temperature and 
stirred for a further 1 h. The reaction mixture was then poured into cold water and the formed 
solid was separated by filtration. 
Compound  5. Yield: 65 %, grey microcrystalline, m.p. 131 °C. Anal. Calcd. for 
C18H18ClN3O5S2: C, 47.42; H, 3.98; N, 9.22 %. Found: C, 47.41; H, 3.97; N, 9.21 %. IR 
(KBr, cm-1): 3047 (stretching of N=C–H), 2937, 2840 (stretching of C–H), 1634 (stretching of 
amide C=O). 1H-NMR (400 MHz, DMSO-d6, δ / ppm): 2.94 (3H, s, NCH3), 3.09 (2H, t, 
indoline CH2), 3.17 (3H, s, NCH3), 3.98 (2H, t, indoline CH2), 7.49–8.14 (7H, m, aromatic 
protons), 8.27 (1H, s, N=CH). MS (m/z): 455 (M+) with all isotopic and other peaks. 
General procedure for the synthesis of 6(a–f) 
Compound 5 (0.010 mol) and the required amine (0.010 mol) were dissolved in THF, 
together with DMAP and pyridine (0.030 mol). The reaction mixture was stirred at room 
temperature for 4 h, after which the reaction mixture was poured into dilute HCl and extracted 
with EtOAc. The organic layer was washed with water, separated, dried over Na2SO4 and 
concentrated under vacuum. The so-obtained crude product was crystallized from a mixture of 
CH2Cl2 and hexane. 
[3,5-Dimethoxy-4-(2-phenoxyethoxy)phenyl](5-nitro-2,3-dihydro-1H-indol-1-yl)methanone (9) 
Compound  7 (0.010 mol) and 8 (0.010 mol) were dissolved in THF, together with 
K2CO3. The reaction mixture was stirred at room temperature for 4 h and then poured into 
water and extracted with EtOAc. The separated, organic layer was dried over Na2SO4 and 
concentrated under vacuum. 
Compound 9. Yield: 80 %; yellow needles; m.p. 93 °C; Anal. Calcd. for C25H24N2O7: C, 
64.65; H, 5.21; N, 6.03 %. Found: C, 64.64; H, 5.20; N, 6.02 %. IR (KBr, cm-1): 2902, 2852 
(stretching of C–H), 1632 (stretching of amide C=O), 1515 (stretching of NO2), 1240 (stretch-
ing of C–O). 1H-NMR (400 MHz, DMSO-d6, δ / ppm): 3.20 (2H, t, indoline CH2), 3.77 (6H, 
s, OCH3), 4.17 (2H, t, indoline CH2), 4.27 (4H, m, OCH2), 6.92–8.16 (10H, m, aromatic 
protons); MS (m/z): 464 (M+) with all isotopic and other peaks. 
(5-Amino-2,3-dihydro-1H-indol-1-yl)[3,5-dimethoxy-4-(2-phenoxyethoxy)phenyl]methanone (10) 
To a suspension of the nitro derivative 9 (0.10 mol) in methanol (50 ml) were added 5 
equivalents SnCl2·2H2O and the reaction mixture was heated at 70 °C for 4 h. Then the 
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mixture was cooled to room temperature, poured into aqueous NH3 and filtered through celite. 
The filtrate was extracted with EtOAc. The separated organic layer was dried over Na2SO4 
and concentrated under vacuum. The product was recrystallized from ethanol. 
Compound 10. Yield: 66 %; brown powder; m.p. 65 °C; Anal. Calcd. for C25H26N2O5: 
C, 69.11; H, 6.03; N, 6.45 %. Found: C, 69.10; H, 6.02; N, 6.44 %. IR (KBr, cm-1): 3445 
(stretching of NH2), 2902, 2852 (stretching of C–H), 1632 (stretching of amide C=O), 1240 
(stretching of C–O). 1H-NMR (400 MHz, DMSO-d6, δ / ppm): 2.94 (2H, t, indoline CH2), 
3.75 (6H, s, OCH3), 3.95 (2H, t, indoline CH2), 4.22 (4H, m, OCH2), 4.95 (2H, bs, NH2), 
6.40–7.78 (10H, m, aromatic protons). MS (m/z): 434 (M+) with all isotopic and other peaks. 
General procedure for the synthesis of 11(a–e) 
Compound 10 (0.010 mol) and the required aromatic sulphonyl chloride (0.010 mol) 
were dissolved in THF, together with DMAP and pyridine (0.030 mol). The reaction mixture 
was stirred at room temperature for 4 h, after which it was poured into dilute HCl and 
extracted with EtOAc. The organic layer was washed with water, separated, dried over 
Na2SO4 and concentrated under vacuum. The crude product was crystallized from a mixture 
of CH2Cl2 and hexane mixture. 
Anti-oxidant activity 
The in vitro antioxidant activity of the test compounds was determined by the DPPH me-
thod5using  L-ascorbic acid (an antioxidant agent) as the positive control. The compounds 
were tested for antioxidant activity at concentrations of 200, 100 and 50 µg/ml. 
Antimicrobial activity 
The in vitro antimicrobial activity of the test compounds was assessed against 24 h cul-
tures of several selected bacteria and fungi. The employed gram positive and gram negative 
bacteria were Escherichia coli, Pseudomonas aeruginosa, Streptococcus pyogenes and Sta-
phylococcus aureus and the used fungi were Candida albicans, Aspergillus niger and Asper-
gillus clavatus. 
The antimicrobial activity of all the compounds was tested using Müller Hinton broth (Hi 
Media M 391) as the nutrient medium for bacterial and Sabouraud Dextrose broth for fungal 
growth. The media were prepared using distilled-deionized water and dispensed in 25 ml 
amounts into 100-mm Petri dishes.The activity was determined by measuring the diameter of 
inhibition zone in millimetres. 
Anti-tuberculosis activity 
All the compounds were screened for their in vitro antimycobacterial activity against 
Mycobacterium tuberculosis by the broth macro dilution method. The activity of the com-
pounds was confirmed by MIC determination against M. tuberculosis. A stock solution of 
each compound (1 mg/ml) was diluted in sterile distilled water to test the range. Each tube 
contained 4 ml sterile Middle Brook 7H9 broth containing albumin-dextrose-catalase, Tween 
80, glycerol and 4 ml of the compound solution was added to make serial double dilutions. 
The tubes were incubated at 37 °C for 7 days and then read visually. The MIC was determined 
as the lowest concentration of the test substance that prevented turbidity. Streptomycin, 
isoniazid, rifampicin and ethambutol were used as the reference standards. 
CONCLUSIONS 
In conclusion, a series of novel indoline derivatives were synthesized and 
subjected to various biological activity tests, viz. antioxidant, antifungal, anti-tu-
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berculosis and antibacterial activity. Most of the compounds showed very good 
antioxidant and anti-infective activities, which suggest that the indoline core has 
a very high therapeutic value and needs to be explored in further studies. 
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ИЗВОД 
СИНТЕЗА И БИОЛОШКА АКТИВНОСТ НЕКИХ ДЕРИВАТА ИНДОЛИНА 
MILIND A. RODE1, SAHEBRAO S RINDHE1 и BHAUSAHEB K KARALE2 
1Depаrtment of Chemistry, New Arts, Commerce and Science College, Ahmednagar- 414001 и 
2Depаrtment of 
Chemistry, Radhabai Kale Mahila Mahavidyalaya, Ahmednagar-414001, India 
Реакцијом индолина са супституисаним бензоил-хлоридом, у присуству K2CO3 у THF, 
добијено је једињење 4 које је, након хлоросулфоновања, преведено у једињење 5. Конден-
зацијом ароматичних амина са молекулом 5 добијени су индолински деривати 6(a–f). Сли-
чан третман 5-нитроидолина супституисаним бензоил-хлоридом дао је нитро дериват 9, који 
је прво редукован калај(II)-хлоридом, а резултујући амин је затим кондензован са ароматич-
ним сулфонил-хлоридом, при чему су добијени индолински деривати 11(a–e). Финални про-
изводи, 6(a–f) и 11(a–e) су тестирани на антибактеријску, антитуберкулозну и антигљивичну 
активност. Неки од синтетизованих деривата су се показали веома активним према одабра-
ним грам-позитивним и грам-негативним микро-ораганизмима, према одређeним сојевима 
гљива, као и према Mycobacterium tuberculosis. Применом in vitro DPPH теста испитане су 
антиоксидативне особине свих синтетизованих индолина, при чему је код већине деривата 
детектована запажена антиоксидативна активност. 
(Примљено 14. априла 2009) 
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